Home/Pipeline/IMA402

IMA402

PRAME-positive solid tumors

Phase 1/2ActiveN/A from source

Key Facts

Indication

PRAME-positive solid tumors

Phase

Phase 1/2

Status

Active

Company

Immatics Biotechnologies

About Immatics Biotechnologies

Immatics Biotechnologies is a clinical-stage company dedicated to developing novel T cell receptor (TCR)-based immunotherapies for cancer. Founded in 2000, it has evolved from a platform-focused entity into a product-driven organization with a strategic focus on the PRAME antigen, expressed in over 50 cancer types. The company's integrated technology platforms enable the discovery of novel intracellular targets and the engineering of high-affinity TCRs against them, forming the basis for its pipeline of Adoptive Cell Therapies (ACT) and TCR Bispecifics. Its lead programs are advancing in clinical trials, positioning Immatics as a key player in the next generation of solid tumor oncology.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other PRAME-positive solid tumors Drugs

Drug	Company	Phase	Status
IMA203	Immatics Biotechnologies	Phase 1/2	Active
IMA203CD8	Immatics Biotechnologies	Phase 1/2	Active
TK-6302	T-Knife Therapeutics	Pre-clinical	Active
IMA402 (TCER®)	Immatics	Phase 1/2	Candidate Selected
Anzu-cel (IMA203C)	Immatics	Phase 1	Active